The study references avoiding co-administration of SSRI's with NSAID's when there is no AD response. There is no mention of SNRI's being evaluated with NSAID's in patient studies.
In fact there is a recommendation to trial antidepressants of other classes in non-reponding SSRI patients.
Perfect opportunity to expand Pristiq market share at the expense of Lexapro and generic SSRI's! Pristiq has the lowest overall discontinuation rate on file with the FDA than any other SNRI branded or generic.
Winning vs whining!!!
Get some Tiger blood pumping out there...